Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study.
Therapeutic advances in medical oncology（2023）
摘要
NCT04414150.
更多查看译文
关键词
advanced solid tumors,antibody,pharmacokinetics,anti-lag,dose-escalation,dose-expansion
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要